Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily Next-in-Class CFTR ...
FDA approves ALYFTREK, a once-daily CFTR modulator for cystic fibrosis in patients 6+ with responsive mutations, including 31 not responsive to other therapies. ALYFTREK showed non-inferiority to TRIKAFTA in ppFEV1 and decreased sweat chloride.
Highlighted Terms
Related News
Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily Next-in-Class CFTR ...
FDA approves ALYFTREK, a once-daily CFTR modulator for cystic fibrosis in patients 6+ with responsive mutations, including 31 not responsive to other therapies. ALYFTREK showed non-inferiority to TRIKAFTA in ppFEV1 and decreased sweat chloride.